Skip to main content
Past event2nd EditionBiopharma

2024 Asia-Pacific Biopharma IP Summit (2nd Edition · Shanghai)

9–11 May 2024Shanghai, China · Holiday Inn Shanghai Hongqiao WestBIPI-2024

About the Conference

About the Conference

The 2nd Asia-Pacific Biopharma IP Summit was hosted by Zhiwen Media and Zhichan Huicui, under the joint guidance of the Shenzhen Pharmaceutical Industry Association, the IP Protection Working Committee of the World Federation of Chinese Medicine Societies (WFCMS) and TCMRR. It took place on 9–11 May 2024 at the Holiday Inn Shanghai Hongqiao West.

Under the theme "IP Empowers Development, Chinese Pharma Innovates the Future", the summit gathered more than 260 industry leaders from across the country — top-tier and innovative pharmaceutical companies, generics manufacturers, leading biotech firms, the judiciary, academia and law firms.

Day one was a dedicated pre-conference seminar on traditional Chinese medicine IP, held alongside the 4th Academic Annual Meeting of the WFCMS IP Protection Working Committee. The two-day main forum that followed examined how the patent linkage system balances innovation and generic competition, IP and legal issues in BD transactions, crystal form patent strategy, patent invalidation challenges, US patent infringement disputes, mRNA patent portfolios and the recognition of offering for sale under centralised procurement listing.

Why Attend

Highlights

  • 01

    260+ industry leaders, with a dedicated pre-conference TCM IP seminar for the first time

  • 02

    Three-day programme: 1 pre-conference seminar + 4 half-day main forum sessions + 3 panel discussions

  • 03

    Full-chain coverage from patent linkage and term extension to crystal forms, mRNA, BD deals and procurement listing

  • 04

    CNIPA, former senior judges, multinational pharma and leading law firms on one stage

Topics & Agenda

Key Topics

Traditional Chinese medicine IP

06
  • Innovation and current issues in TCM IP protection
  • Patent infringement determination for TCM
  • Patent strategies for same-name and same-formula medicines
  • China's TCM patent examination policy and standards under the new guidelines
  • Patent portfolio analysis of typical TCM products
  • Managing TCM intellectual property

Patent linkage and term extension

04
  • Comparing drug patent linkage systems in China, the US and Korea
  • Reviewing and analysing China's drug patent linkage implementation with big data
  • How the amended Implementing Regulations affect infringement and grant/invalidation practice in biopharma
  • Exploring patent term extension for pharmaceuticals under the amended Implementing Regulations

Filing practice and risk control

06
  • Supplementary experimental data in biopharma grant and invalidation disputes
  • Patent ownership compliance risks in industry-academia-research collaboration
  • Building patent portfolios from a litigation perspective
  • Overseas patent filing and risk prevention
  • Patent protection strategies for biological sequences
  • Invalidation strategy and patent protection — lessons from recent biopharma invalidation cases

Industrialisation and internationalisation

06
  • Legal issues in cross-border licensing, IP transactions and disputes
  • Internationalisation of Chinese pharmaceutical companies under the new landscape
  • Patent issues and trends in the mRNA industry
  • Drug crystal form patent portfolio strategy
  • IP and legal considerations in BD transactions
  • Recognising offering for sale under centralised drug procurement listing in China

Overview of Speakers

Speakers

  • Shang Jiangang

    Shang Jiangang

    School of Economics and Law, Shanghai University of Political Science and Law

    Associate Professor (Pre-conference Chair)

  • Wang Heping

    Wang Heping

    IP Protection Working Committee, WFCMS

    Chairman (Opening Address)

  • Liu Wenqiu

    Liu Wenqiu

    Shenzhen Enterprise Science and Technology Innovation Promotion Association

    Executive Chairman (Opening Address)

  • Ma Zhiguo

    Ma Zhiguo

    Xi'an Jiaotong University

    Dean of the IP School, Vice Chairman of the WFCMS IP Committee

  • Zheng Xiyuan

    Zheng Xiyuan

    Qiancheng Law Firm

    Partner, Deputy Director of Patent Center

  • Dou Xiarui

    Dou Xiarui

    IP Protection Working Committee, WFCMS

    Standing Director

  • Song Jiangxiu

    Pharmaceutical and Biological Invention Examination Department, CNIPA

    Second-Level Inspector (Online Speaker)

  • Liu Cailian

    Liu Cailian

    SZYY Group Pharmaceutical

    IP Director

  • Zhang Hongliu

    Zhang Hongliu

    China Patent Protection Association

    Vice Chairman of the Pharmaceutical Committee, Standing Director of the WFCMS IP Committee

  • Wang Weibin

    Wang Weibin

    Shanghai Bishing Law Firm

    Managing Partner (Chair)

  • Cheng Yongshun

    Cheng Yongshun

    IP Tribunal, Beijing High People's Court

    Former Deputy Chief Judge

  • Song Jiemei

    Song Jiemei

    Nanjing Chia Tai Tianqing Pharmaceutical

    Deputy Director of Patent Technology

  • Qi Fang

    Qi Fang

    Fangda Partners

    Partner

  • Li Na

    Li Na

    Fangda Partners

    Partner

  • Xue Xufei

    Xue Xufei

    Zhongwen Law Firm

    Partner

  • Yan Chunhui

    Yan Chunhui

    Zhong Lun Law Firm

    Non-Equity Partner (Chair)

  • Wang Xuhong

    Wang Xuhong

    Suzhou Shengran Weian Pharmaceutical Technology

    CEO

  • Zhang Jiandong

    Zhang Jiandong

    Naval Medical University

    Deputy Director, Technology Transfer Office

  • Li Lingchuan

    Li Lingchuan

    FMC Corporation

    Head of IP, Asia Pacific

  • Zhang Hongchun

    Zhang Hongchun

    Beijing Caihe Law Firm

    Equity Partner

  • Geng Yuanshuo

    Geng Yuanshuo

    Suzhou Jinshang IP Agency

    Partner (Chair)

  • Zhang Beibei

    Zhang Beibei

    China Chamber of Commerce for Import and Export of Medicines and Health Products

    Director of Legal Affairs

  • Hao Xuemin

    Hao Xuemin

    CanSino Biologics

    Head of IP

  • Li Caihui

    Li Caihui

    Shanghai Juntuo Biomedical Technology

    Head of IP

  • Wu Hao

    Wu Hao

    Shenzhen Rhegen Biotechnology

    Head of IP

  • Zhang Xiaoyu

    Zhang Xiaoyu

    Crystal Pharmatech

    R&D Director

  • Yao Cong

    Yao Cong

    Innovent Biologics (Suzhou)

    Executive Director, Head of IP

  • Cao Lirong

    Cao Lirong

    Tongji University

    Deputy Director, Center for Pharmaceutical Law and IP Research

Panel Discussions

Panel: IP challenges and opportunities in TCM innovation

Panel: IP challenges and opportunities in TCM innovation

Host: Shang Jiangang (Associate Professor, Shanghai University of Political Science and Law)

Panellists:

  • Zheng Yongfeng (Vice President and Chief IP Officer, Tasly Holding Group)
  • Li Shuangqi (President, Handan Huadan Traditional Chinese Orthopaedic Hospital)
  • Liu Cailian (IP Director, SZYY Group Pharmaceutical)
  • Zheng Xiyuan (Partner, Qiancheng Law Firm)
  • Zhang Yu (Assistant to General Manager, Tiandao Zhengxin Industrial Operation)
Panel: Patent term extension for pharmaceuticals under the amended Implementing Regulations

Panel: Patent term extension for pharmaceuticals under the amended Implementing Regulations

Host: Cheng Yongshun (Former Deputy Chief Judge, IP Tribunal, Beijing High People's Court)

Panellists:

  • Jin Miaojing (Head of IP, Frontier Biotechnologies)
  • Wu Hesong (Head of IP Department, Jiangsu Zhengda Fenghai Pharmaceutical)
  • Gao Wei (Senior IP Director, Yangzijiang Pharmaceutical Group)
  • Wang Xuhong (CEO, Suzhou Shengran Weian Pharmaceutical Technology)
  • Xue Xufei (Partner, Zhongwen Law Firm)
Panel: Hot issues in pharmaceutical patent invalidation

Panel: Hot issues in pharmaceutical patent invalidation

Host: Xu Jiechao (Partner, Shanghai Bishing Law Firm)

Panellists:

  • Li Caihui (Head of IP, Shanghai Juntuo Biomedical Technology)
  • Jiang Xiaoman (Assistant General Manager, Legal and Compliance, Livzon Pharmaceutical Group)
  • Wang Lili (Founder, Nuozhong Heyi Pharmaceutical)
  • Teng Jinlin (Director, Suzhou Jinshang IP Agency)

Hosted By

Organisers

  • Zhiwen Media
  • Zhichan Huicui

Supported By

Supporters

  • IP Protection Working Committee, World Federation of Chinese Medicine SocietiesIP Protection Working Committee, World Federation of Chinese Medicine Societies
  • Shenzhen Pharmaceutical Industry AssociationShenzhen Pharmaceutical Industry Association
  • Skin and Soft Tissue Repair and Reconstruction Technology Branch, China Medicinal Biotech AssociationSkin and Soft Tissue Repair and Reconstruction Technology Branch, China Medicinal Biotech Association

BIPI-2024 · see you at the next edition

For the full agenda or registration details, get in touch with the organising committee — we usually reply within one business day.

Full Report

Read the full post-event report

Originally published on our WeChat account, including the full session recap and photo gallery.